Abbott India Limited

ABBOTINDIA

INE358A01014

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 05:18:34 2024-06-26 EDT			5-day change	1st Jan Change
27,647 ^INR	+2.77%		+2.71%	+20.98%

06-11	Abbott India Limited Announces Resignation of Sabina Ewing as Director, Effective June 12, 2024	CI
05-09	Drugmaker Abbott India posts Q4 profit rise on higher sales	RE

Abbott India Limited Announces Retirement of Rajiv Sonalker as Chief Financial Officer of the Company Effective Close of Business Hours on June 30, 2023

March 17, 2023 at 06:39 am

Abbott India Limited announced retirement of Mr. Rajiv Sonalker as Chief Financial Officer of the Company effective close of business hours on June 30, 2023, consequent to his retirement from the employment of the Company.

Latest news about Abbott India Limited

Abbott India Limited Announces Resignation of Sabina Ewing as Director, Effective June 12, 2024	06-11	CI
Drugmaker Abbott India posts Q4 profit rise on higher sales	05-09	RE
Abbott India Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-09	CI
Abbott India Limited Appoints Murari Ranganathan as Commercial Director	04-12	CI
Abbott India's Managing Director Exits	03-19	MT
Abbott India Limited Announces Resignation of Sandeep Reddy - Commercial Director - Women's Health, Metabolics and International Business, with Effect from June 5, 2024	03-15	CI
Abbott India Names Managing Director	03-13	MT
GSK India arm's Q3 profit falls on government price cap	02-12	RE
Abbott India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01-14	CI
Abbott India Managing Director to Step Down in March 2024	12-19	MT
Abbott India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
INDIA STOCKS-Indian shares set for muted opening; Delta Corp in focus after tax notice	23-09-24	RE
Abbott India warns of laxatives shortage in tussle with Goa regulator	23-09-22	RE
Goa state warns Abbott India on antacid license suspension	23-09-14	RE
Abbott India Limited Approves Appointment of Sangeeta Shetty as Company Secretary, Effective September 14, 2023	23-08-09	CI
Abbott India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-09	CI
Abbott India Limited Appoints Ms Richa Tripathi as Associate Director, Effective August 3, 2023	23-07-24	CI
INDIA STOCKS-Indian shares recover from weak start on buying at key levels	23-05-22	RE
Abbott India Limited Approves the Appointment of Sridhar Kadangode as Chief Financial Officer, Effective July 1, 2023	23-05-19	CI
Abbott's India arm posts 9.5% rise in fourth-quarter profit	23-05-19	RE
Abbott India Limited Approves the Appointment of Mahadeo Karnik as an Additional and Non-Executive Director on the Board, Effective July 1, 2023	23-05-19	CI
Abbott India Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-19	CI
Abbott India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-19	CI
Abbott India Limited Announces the Resignation of Krupa Anandpara as Company Secretary and Compliance Officer, Effective on June 30, 2023	23-04-07	CI
Abbott India CFO Retires	23-03-17	MT

Chart Abbott India Limited

Duration

Period

More charts

Company Profile

Abbott India Limited is an India-based company that is engaged in the pharmaceuticals business. The Company has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. It provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolic, multi-specialty, and vaccines, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), Duvadilan (preterm labor), and others. It offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure, Glucerna, and others.

Sector

Pharmaceuticals

Calendar

2024-07-18 - Détachement de for final dividend

More about the company

Income Statement Evolution

More financial data

Ratings for Abbott India Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBOTT INDIA LIMITED	+20.98%	6.85B
ELI LILLY AND COMPANY	+55.19%	815B
NOVO NORDISK A/S	+45.91%	654B
JOHNSON & JOHNSON	-6.09%	354B
MERCK & CO., INC.	+21.92%	337B
ASTRAZENECA PLC	+19.68%	247B
ROCHE HOLDING AG	+3.64%	229B
NOVARTIS AG	+14.06%	219B
AMGEN INC.	+10.86%	171B
PFIZER, INC.	-2.78%	159B

Other Pharmaceuticals